| Project/Area Number |
09470082
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | TOKYO INSTITUTE OF TECHNOLOGY |
|---|
Principal Investigator |
HANDA Hiroshi Tokyo Institute of Technology, Frontier Collaborative Research Center, Professor, フロンティア創造共同研究センター, 教授 (80107432)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARISAKA Fumio Tokyo Institute of Technology, Faculty of Bio sciences and Biotechnology, Associ, 生命理工学部, 助教授 (80133768)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥11,800,000 (Direct Cost: ¥11,800,000)
Fiscal Year 1998: ¥5,200,000 (Direct Cost: ¥5,200,000)
Fiscal Year 1997: ¥6,600,000 (Direct Cost: ¥6,600,000)
|
|---|
| Keywords | Gene therapy / Molecular recognition / Self-assembly / Cellular directivity / Virus component / Capsid protein / Virus-like particules / Virus vector |
|---|
| Research Abstract |
It became possible to make viruses which have been hazardous for the human into useful components by the development of gene-technology and basic studies on virology. Recombinant virus vector has been found much worthy in gene transfer method for maintaining the long term growth of mammalian cells in vitro. A SV40-adenovirus recombinant vector was used immortalize the human bone marrow stromal cells. The chimeric virus vector was found more efficient than DNA transfection method. AAV-2, consists of three capsid proteins at a ratio of VP1 : VP2 : VP3=l0 : 1 : 1. AAV-2 is supported to encapsidate the genome into a pre-formed pro-capsid. Characterization of self assembled capsid as well the mechanism of the assembly of the capsid deserve much importance in studying viral capsid for in vitro system. VLP has been purified from insect cells by infecting with recombinant bacurovirus, containing VP2 coding region alone or co-infection. Thus, various factors participating in VLP formation by self assembly and in partial dissociation and re-assembly of VLP components were elucidated. Accordingly, basic study systems of the application of the recombinant virus capsid protein to gene therapy by using vector of novel genes has been established in this study.
|
